ResMed price target raised to $298 from $274 at KeyBanc

KeyBanc raised the firm’s price target on ResMed (RMD) to $298 from $274 and keeps an Overweight rating on the shares. The firm believes ResMed’s Q4 results and initial FY26 commentary largely supported its thesis of sustained mid-to-high-single-digit organic growth, with opportunities for further margin expansion, despite ongoing investor concern around perceived headwinds such as GLP-1s.